Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amgen

298.81
+3.001.01%
Post-market: 298.810.00000.00%19:54 EDT
Volume:1.96M
Turnover:582.45M
Market Cap:160.87B
PE:24.43
High:299.37
Open:295.24
Low:293.14
Close:295.81
52wk High:335.88
52wk Low:253.30
Shares:538.36M
Float Shares:536.99M
Volume Ratio:0.92
T/O Rate:0.36%
Dividend:9.26
Dividend Rate:3.10%
EPS(TTM):12.23
EPS(LYR):7.62
ROE:99.14%
ROA:7.51%
PB:21.66
PE(LYR):39.23

Loading ...

Amgen Inc. Stock Rallies 3.5%, Outperforms Peers

Dow Jones
·
Sep 20

Sector Update: Health Care Stocks Mixed Friday Afternoon

MT Newswires Live
·
Sep 20

Amgen's Uplizna Receives European Human Medicines Committee Recommendation for IgG4-Related Disease

MT Newswires Live
·
Sep 19

Apple, Amgen Share Gains Contribute To Dow's 118-Point Jump

Dow Jones
·
Sep 19

Organon, Shanghai Henlius Say EU Approves Denosumab Biosimilars

MT Newswires Live
·
Sep 19

Ema's Chmp: Recommended Extending Therapeutic Indication of Uplizna (Inebilizumab) to Include Treatment of Adult Patients With Active Igg4-Rd

THOMSON REUTERS
·
Sep 19

Alnylam Joins Alliance for Genomic Discovery

MT Newswires Live
·
Sep 18

Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)

TIPRANKS
·
Sep 18

Amgen Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Sep 12

Handan City Market Supervision Bureau in Hebei Province Organizes "Party Member Double Registration, Drug Safety into Ten Thousand Homes" Science Education Campaign

Deep News
·
Sep 11

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Benzinga_recent_news
·
Sep 10

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 Ascend Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

THOMSON REUTERS
·
Sep 09

Verizon, Merck Share Losses Contribute To Dow's 118-Point Drop

Dow Jones
·
Sep 08

Hansoh Pharmaceutical Secures NMPA Approval for New Indication of XINYUE (Inebilizumab) for IgG4-Related Disease

Reuters
·
Sep 06

Amgen Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Sep 05

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

Benzinga
·
Sep 05

Amgen Announces Promising Phase 2 Study Results for New Obesity Drug MariTide, Paving Way for Phase 3 Trials

Reuters
·
Sep 04

Amgen Coverage Assumed by Raymond James at Market Perform

Dow Jones
·
Sep 04

ZAI LAB (09688): Latest Update on Amgen's Bemarituzumab FORTITUDE-101 Phase III Clinical Trial

Stock News
·
Sep 03

Zai Lab Ltd. Awaits Results from FORTITUDE-102 Trial for Bemarituzumab in Gastric Cancer Treatment Following Attenuated Survival Benefit in Phase 3 FORTITUDE-101 Study

Reuters
·
Sep 03